SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

07 Nov 2023 Evaluate
The Revenue for the quarter ended  September 2023 of Rs. 1400.95 millions grew by 24.89 % from Rs. 1121.72 millions.A comparatively good net profit growth of 41.64% to Rs. 238.84 millions was reported for the quarter ended September 2023 compared to Rs. 168.62 millions of previous same quarter.Operating profit surged to 342.19 millions from the corresponding previous quarter of 311.67 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 1400.95 1121.72 24.89 2721.16 2135.27 27.44 4609.38 5300.49 -13.04
Other Income 24.67 26.05 -5.30 53.85 49.62 8.52 94.89 75.77 25.23
PBIDT 342.19 311.67 9.79 816.28 647.70 26.03 1383.87 2215.62 -37.54
Interest 4.60 7.75 -40.65 12.76 13.56 -5.90 30.84 41.98 -26.54
PBDT 337.59 303.92 11.08 803.52 634.14 26.71 1353.03 2173.64 -37.75
Depreciation 39.81 29.73 33.91 79.36 58.58 35.47 118.15 101.18 16.77
PBT 297.78 274.19 8.60 724.16 575.56 25.82 1234.88 2072.46 -40.41
TAX 58.94 105.57 -44.17 200.20 154.44 29.63 336.30 554.35 -39.33
Deferred Tax -26.44 0.91 -3005.49 15.19 3.91 288.49 29.49 32.46 -9.15
PAT 238.84 168.62 41.64 523.96 421.12 24.42 898.58 1518.11 -40.81
Equity 160.97 160.97 0.00 160.97 160.97 0.00 160.97 160.97 0.00
PBIDTM(%) 24.43 27.79 -12.09 30.00 30.33 -1.11 30.02 41.80 -28.18

Supriya Lifescience Share Price

636.90 -1.05 (-0.16%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×